- Home
- ONDS vs GOSS Comparison
ONDS vs GOSS Comparison
Compare ONDS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- GOSS
- Stock Information
- Founded
- ONDS 2014
- GOSS 2015
- Country
- ONDS United States
- GOSS United States
- Employees
- ONDS N/A
- GOSS N/A
- Industry
- ONDS Telecommunications Equipment
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- GOSS Health Care
- Exchange
- ONDS Nasdaq
- GOSS Nasdaq
- Market Cap
- ONDS 1.4B
- GOSS 347.8M
- IPO Year
- ONDS N/A
- GOSS 2019
- Fundamental
- Price
- ONDS $5.86
- GOSS $2.47
- Analyst Decision
- ONDS Strong Buy
- GOSS Strong Buy
- Analyst Count
- ONDS 3
- GOSS 4
- Target Price
- ONDS $4.67
- GOSS $8.50
- AVG Volume (30 Days)
- ONDS 49.3M
- GOSS 3.1M
- Earning Date
- ONDS 08-12-2025
- GOSS 08-05-2025
- Dividend Yield
- ONDS N/A
- GOSS N/A
- EPS Growth
- ONDS N/A
- GOSS N/A
- EPS
- ONDS N/A
- GOSS N/A
- Revenue
- ONDS $16,131,404.00
- GOSS $40,237,000.00
- Revenue This Year
- ONDS $246.94
- GOSS N/A
- Revenue Next Year
- ONDS $161.09
- GOSS $30.65
- P/E Ratio
- ONDS N/A
- GOSS N/A
- Revenue Growth
- ONDS 75.16
- GOSS N/A
- 52 Week Low
- ONDS $0.57
- GOSS $0.66
- 52 Week High
- ONDS $6.19
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ONDS 79.19
- GOSS 68.08
- Support Level
- ONDS $3.20
- GOSS $2.38
- Resistance Level
- ONDS $4.33
- GOSS $2.65
- Average True Range (ATR)
- ONDS 0.54
- GOSS 0.15
- MACD
- ONDS 0.17
- GOSS 0.03
- Stochastic Oscillator
- ONDS 89.02
- GOSS 76.67
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.